Annual EBITDA
-$62.20 M
-$40.60 M-187.99%
31 December 2023
Summary:
Verrica Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$62.20 million, with the most recent change of -$40.60 million (-187.99%) on 31 December 2023. During the last 3 years, it has fallen by -$22.77 million (-57.74%). VRCA annual EBITDA is now -3151.28% below its all-time high of -$1.91 million, reached on 31 December 2016.VRCA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.14 M
-$5.66 M-39.06%
30 September 2024
Summary:
Verrica Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.14 million, with the most recent change of -$5.66 million (-39.06%) on 30 September 2024. Over the past year, it has increased by +$2.79 million (+12.18%). VRCA quarterly EBITDA is now -4252.99% below its all-time high of $485.00 thousand, reached on 30 September 2022.VRCA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$74.39 M
+$2.79 M+3.62%
30 September 2024
Summary:
Verrica Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$74.39 million, with the most recent change of +$2.79 million (+3.62%) on 30 September 2024. Over the past year, it has dropped by -$28.55 million (-62.30%). VRCA TTM EBITDA is now -12950.88% below its all-time high of -$570.00 thousand, reached on 31 March 2017.VRCA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRCA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -188.0% | +12.2% | -62.3% |
| 3 y3 years | -57.7% | -72.4% | -118.6% |
| 5 y5 years | -184.6% | -231.6% | -159.1% |
VRCA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -188.0% | at low | -4253.0% | +12.2% | -260.5% | +3.6% |
| 5 y | 5 years | -188.0% | at low | -4253.0% | +12.2% | -260.5% | +3.6% |
| alltime | all time | -3151.3% | at low | -4253.0% | +12.2% | <-9999.0% | +3.6% |
Verrica Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.14 M(+39.1%) | -$74.39 M(-3.6%) |
| June 2024 | - | -$14.48 M(-18.0%) | -$77.18 M(+5.0%) |
| Mar 2024 | - | -$17.67 M(-20.0%) | -$73.48 M(+18.1%) |
| Dec 2023 | -$62.20 M(+188.0%) | -$22.09 M(-3.7%) | -$62.20 M(+35.7%) |
| Sept 2023 | - | -$22.93 M(+112.7%) | -$45.84 M(+104.5%) |
| June 2023 | - | -$10.78 M(+68.8%) | -$22.42 M(+8.6%) |
| Mar 2023 | - | -$6.39 M(+11.4%) | -$20.64 M(-4.2%) |
| Dec 2022 | -$21.60 M(-28.8%) | -$5.73 M(-1281.6%) | -$21.54 M(-9.8%) |
| Sept 2022 | - | $485.00 K(-105.4%) | -$23.88 M(-33.8%) |
| June 2022 | - | -$9.00 M(+23.5%) | -$36.05 M(-4.4%) |
| Mar 2022 | - | -$7.29 M(-9.7%) | -$37.71 M(+24.4%) |
| Dec 2021 | -$30.31 M(-23.1%) | -$8.07 M(-30.9%) | -$30.31 M(-10.9%) |
| Sept 2021 | - | -$11.68 M(+9.6%) | -$34.03 M(+6.6%) |
| June 2021 | - | -$10.66 M(<-9900.0%) | -$31.91 M(+7.3%) |
| Mar 2021 | - | $103.00 K(-100.9%) | -$29.74 M(-24.6%) |
| Dec 2020 | -$39.43 M | -$11.79 M(+23.3%) | -$39.43 M(+12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$9.56 M(+12.6%) | -$35.06 M(+11.1%) |
| June 2020 | - | -$8.49 M(-11.4%) | -$31.57 M(+5.0%) |
| Mar 2020 | - | -$9.59 M(+29.3%) | -$30.07 M(+7.6%) |
| Dec 2019 | -$27.95 M(+27.9%) | -$7.42 M(+22.1%) | -$27.95 M(-2.6%) |
| Sept 2019 | - | -$6.07 M(-13.1%) | -$28.71 M(-0.9%) |
| June 2019 | - | -$6.99 M(-6.4%) | -$28.96 M(+5.6%) |
| Mar 2019 | - | -$7.47 M(-8.7%) | -$27.44 M(+25.5%) |
| Dec 2018 | -$21.86 M(+390.4%) | -$8.18 M(+29.3%) | -$21.86 M(+44.6%) |
| Sept 2018 | - | -$6.33 M(+15.8%) | -$15.11 M(+49.0%) |
| June 2018 | - | -$5.46 M(+189.5%) | -$10.14 M(+75.7%) |
| Mar 2018 | - | -$1.89 M(+31.7%) | -$5.78 M(+29.6%) |
| Dec 2017 | -$4.46 M(+133.0%) | -$1.43 M(+5.6%) | -$4.46 M(+47.4%) |
| Sept 2017 | - | -$1.36 M(+24.0%) | -$3.02 M(+81.6%) |
| June 2017 | - | -$1.09 M(+92.1%) | -$1.67 M(+192.1%) |
| Mar 2017 | - | -$570.00 K | -$570.00 K |
| Dec 2016 | -$1.91 M | - | - |
FAQ
- What is Verrica Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals annual EBITDA year-on-year change?
- What is Verrica Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Verrica Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals TTM EBITDA year-on-year change?
What is Verrica Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VRCA is -$62.20 M
What is the all time high annual EBITDA for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.91 M
What is Verrica Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, VRCA annual earnings before interest, taxes, depreciation & amortization has changed by -$40.60 M (-187.99%)
What is Verrica Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VRCA is -$20.14 M
What is the all time high quarterly EBITDA for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $485.00 K
What is Verrica Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, VRCA quarterly earnings before interest, taxes, depreciation & amortization has changed by +$2.79 M (+12.18%)
What is Verrica Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VRCA is -$74.39 M
What is the all time high TTM EBITDA for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$570.00 K
What is Verrica Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, VRCA TTM earnings before interest, taxes, depreciation & amortization has changed by -$28.55 M (-62.30%)